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McCune–Albright syndrome (MAS) is a rare congenital disorder characterized by the 
association of endocrine and nonendocrine anomalies caused by somatic activating 
variants of GNAS. The mosaic state of variants makes the clinical presentation extremely 
heterogeneous depending on involved tissues. Biological samples bearing a low level of 
mosaicism frequently lead to false-negative results with an underestimation of causative 
molecular alterations, and the analysis of biopsies is often needed to obtain a molecular 
diagnosis. To date, no reliable analytical method for the noninvasive testing of blood is 
available. This study was aimed at validating a novel and highly sensitive technique, the 
digital PCR (dPCR), to increase the detection rate of GNAS alterations in patients with a 
clinical suspicion of MAS and, in particular, in blood. We screened different tissues (blood, 
bone, cutis, ovary, and ovarian cyst) collected from 54 MAS patients by different technical 
approaches. Considering blood, Sanger was unable to detect mutations, the allele-
specific PCR and the co-amplification at lower denaturation temperature had a 9.1% and 
18.1% detection rate, respectively, whereas the dPCR reached a 37.8% detection rate. In 
conclusion, the dPCR resulted in a cost-effective, reliable, and rapid method allowing the 
selective amplification of low-frequency variants and able to improve GNAS mutant allele 
detection, especially in the blood.
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INTRODUCTION
The McCune–Albright syndrome (MAS, MIM #174800) is a rare congenital disorder that comprises 
the clinical triad of endocrinopathies, cafè-au-lait pigmented skin lesions (SP), and fibrous 
dysplasia of bone (FD). The endocrine dysregulation may include various autonomous hormonal 
hyperfunctions, such as precocious puberty, hyperthyroidism, growth hormone excess, adrenal 
hyperplasia, hypophosphatemic osteomalacia, and GH- and/or PRL- secreting pituitary tumors 
(McCune, 1936; Albright et al., 1937; Robinson et al., 2016; Boyce et al., 2017). In particular, the more 
frequent and studied alterations of the endocrine glands are the gonadal hyperfunction (characterized 
by episodes of hyperestrogenism with a consequent reduction in gonadotropin secretion), thyroid 
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abnormalities (nodular goiter with nodules >1cm), and the 
GH-IGF1 axis hyperactivity (Matarazzo et al., 2006; Tessaris et al., 
2012; Tessaris  et al., 2006).
The disease demonstrated sporadic occurrence, phenotypic 
heterogeneity, variable involvement of different endocrine 
glands, and a pattern of skin and bone lesions following the lines 
of the embryologic development, thus it was proposed that MAS 
derived from a postzygotic genetic defect, leading to a mosaic 
distribution of mutated cells. Such hypothesis was confirmed 
by the identification of somatic activating variants affecting 
the alpha subunit of the stimulatory G protein (Gsα, encoded 
by GNAS, MIM*139320) (Landis et al., 1989; Weinstein et al., 
1991; Schwindinger et al., 1992; Candeliere et al., 1997). Most 
gain-of-function GNAS genetic variants occurred at the Arg202 
residue (historically and still frequently reported as Arg201) 
and determined the constitutional activation of the stimulatory 
G protein and, consequently, of adenylyl cyclase (Landis et al., 
1989). The tissue-by-tissue study by droplet digital PCR (ddPCR) 
of autopsy samples from a patient confirmed that MAS can affect 
a wider range of tissues, leading to extraskeletal manifestations, 
such as gastrointestinal reflux and/or polyps, pancreatitis, 
hepatobiliary disease, cardiac disease (sudden death, tachycardia, 
high output heart failure, and aortic root dilatation), platelet 
dysfunction, and cancer (bone, breast, testes, and thyroid) 
(Salpea and Stratakis, 2014; Vasilev et al., 2014).
The mosaic state of MAS/FD-associated variants determines an 
extremely heterogeneous presentation of clinical manifestations 
in patients, depending upon the extent to which affected tissues 
are involved, and makes establishing the correct molecular 
diagnosis a real challenge. As a matter of fact, the investigation of 
biological samples, such as peripheral blood that typically bears a 
low level of mosaicism, leads to high rates of false-negative results 
and the underestimation of causative molecular alterations in 
MAS/FD patients (Hannon et al., 2003; Karadag et al., 2004; 
Lumbroso et al., 2004; Lietman et al., 2005; Kalfa et al., 2006; 
Kuznetsov et al., 2008; Liang et al., 2011; Narumi et al., 2013).
A real help to overcome the underestimation of mosaic 
variants will possibly arrive by the development of single-cell 
sequencing technologies that, actually, are under development as 
a liquid biopsy tool to investigate cancer patients noninvasively. 
In particular, limits, such as elevated costs and obtaining enough 
genetic material for library preparation, make these methods still 
far from the adoption by the health care system, but, in the next 
future, they could represent a promising tool for somatic variants 
analysis (Wei et al., 2017; Zhu et al., 2018).
Different technical approaches, each with its pros and cons, 
had been developed in the past years with the aim to detect MAS/
FD-associated variants. The first attempt dates back to 1997 
when Candeliere and colleagues, (1997) combined consecutive 
and repeated cycles of PCR amplification with site-directed 
mutagenesis to generate a PCR product from the normal allele 
susceptible to restriction nuclease digestion. Other researchers 
tried to overcome the problem by using a peptide nucleic 
acid (PNA) primer to inhibit the amplification of the normal 
allele, combining PNA probes with the fluorescence resonance 
energy transfer (FRET) technique, pyrosequencing, next-
generation sequencing (NGS), or ddPCR (Hannon et al., 2003; 
Karadag  et  al., 2004; Liang et al., 2011; Narumi et al., 2013; 
Vasilev et al., 2014). Selective enrichment methods reached good 
levels in low-abundance variants detection, but they presented 
several limits as being expensive, time-consuming, and leading 
to an elevated risk of generating PCR artifacts and cross-
contamination (Qin et al., 2016). In particular, the NGS approach 
with deep sequence coverage enhances sensitivity and allows for 
accurate quantification of the level of mosaicism, but the use of 
a customized DNA probe library followed by deep NGS analysis 
with a mean coverage depth per base of approximately 800× 
translates into a cost-per-patient analysis too high for the health 
care system.
The improvement in the sensitivity of genetic tests for defects 
in mosaic state associated with MAS/FD is an important step to 
improve the diagnosis of patients, thus the aim of the present 
study was to set up and validate a novel technique, digital 
PCR (dPCR), to increase the detection rate of activating GNAS 
alterations in different tissue samples. The dPCR is a method 
used for absolute quantification of nucleic acids based on the 
amplification of single molecules of template with target-specific 
fluorescent-labeled assays. The subsequent analysis yields the 
relative or absolute quantification results from the raw imaging 
data. It was conceived in 1992 and applied to the quantification 
of KRAS mutations in DNA from colorectal cancer patients. 
This approach has many potential applications, including the 
detection and quantification of low-level pathogens, rare genetic 
sequences, copy number variations (CNVs), gene expression in 
single cells, and quantification of circulating miRNA expression. 
It works by partitioning a sample of DNA or cDNA into many 
individual parallel PCR reactions and allows the detection of 
sequence variants present at a very low frequency in a pool of 
wild-type background (Sykes et al., 1992; Vogelstein and Kinzler, 
1999). According to the manufacturer’s specification, optimized 
dPCR assays should detect and quantify rare mutant prevalence 
to ≤0.1%.
In this study, we evaluated the usefulness of a novel technique, 
the dPCR, to obtain a molecular confirmation in patients with a 
clinical suspicion of MAS/FD by the screening of different tissues 
collected from a case series of 54 MAS/FD patients using and 
comparing different technical approaches. In particular, thanks 
to the expected ability of dPCR to detect low-abundance somatic 
single-nucleotide alterations, our main aim was to find GNAS 
mutant alleles in blood samples from MAS/FD patients.
MATERIALS AND METHODS
Patients and Biological Samples
The present study included 54 patients with a clinical diagnosis 
of MAS/FD. For 41 patients, a single tissue only was available 
for the analysis [24 blood samples (BL) and 17 biopsies: 10 bone 
(BO), 4 cutis (CB), 3 ovarian tissue (OT), and/or ovarian cyst 
(OC)], whereas for 13 patients, we investigated and compared 
the DNA extracted from different tissues (2 BL+BO, 6 BL+CB/
fibroblasts from cutaneous biopsy, and 4 BL+OT/OC). Overall, 
79 different samples were tested for the presence of MAS/
FD-related activating variants within GNAS exon 8. The MAS 
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clinical suspicion was based on the presence of at least persistent 
and/or recurrent ovarian cysts associated with peripheral 
precocious puberty or another typical sign of MAS between 
cafè-au-lait skin spots or fibrous bone dysplasia. Clinical details, 
including some patient-specific additional features, and the 
molecular diagnosis are resumed in the Supplementary Table 1. 
Wild-type controls were healthy people, whereas mutant controls 
were MAS patient-derived GNAS mutated tissues. Informed 
consent for genetic studies was obtained from all subjects 
involved in the study.
DNA samples were extracted from peripheral blood in EDTA 
collection tubes (Flexigene DNA kit, Qiagen, Germany) and 
fresh or FFPE tissue samples (GentraPuregene tissue kit, Qiagen, 
Germany), according to the manufacturer’s instructions.
Techniques for the Detection of GNAS 
MAS-Related Genetic Variants
To investigate the presence of heterozygous gain-of-function GNAS 
variants c.604C > T/p.Arg202Cys and c.605G > A/p.Arg202His, 
commonly reported in the literature as Arg201 (in accordance with 
the guidelines recommended by the Human Genome Variation 
Society (HGVS), http://www.hgvs.org/mutnomen/, for a uniform 
and an unequivocal description of sequence variants in DNA and 
protein sequences, the nucleotide and protein numbering used 
in the present article was based on the Locus Reference Genomic 
(LRG) sequence, https://www.lrg-sequence.org/, covering  the 
GNAS transcript NM_001077488.2; the GNAS mutations database 
available at http://databases.lovd.nl/shared/genes/GNAS) associated 
with the MAS/FD phenotype, different experimental techniques 
were used: Sanger sequencing, allele-specific PCR (AS-PCR), allele-
specific PCR-based TaqMan genotyping with co-amplification at 
lower denaturation temperature (COLD-MAMA PCR), and dPCR.
Detection limits (LOD) of each method, defined as the lowest 
concentration that can be reliably distinguished from healthy 
controls, are a consequence of assay specificity, sample quality/
handling, and PCR inhibitors. For the empirical determination 
of detection limits, we applied the strategy of analyzing no DNA 
template controls (NTCs, contamination monitors), wild-type 
negative controls (WTCs, false-positive monitors), and a serial 
dilution of mutant positive controls in a background of wild-
type DNA (MTCs, positive controls for thresholding and making 
limit of detection calls).
The GNAS exon 8 was amplified using the specific couple of 
primers 5’-ACTCTGAGCCCTCTTTCCAA-3’ and 5’-GGTAAC 
AGTTGGCTTACTGG-3’ (thermal conditions: 94°C/5’, 40 cycles 
at 94°C/30”, 58°C/30”, and 72°C/30”, 72°C/5’). Sanger sequencing 
was performed using the AmpliTaqBigDye Terminator kit and 
the 3110xl Genetic Analyzer (Applied Biosystems, Foster City, 
CA, USA).
Amplicons subjected to sequencing were also used as template 
for AS-PCRs, visualized and analyzed on 3% agarose gels, that 
was shown to be able to discriminate wild-type and mutant 
alleles using sequence-specific primers (c.604C 5′-GATTCCAG 
AAGTCAGGACACG-3′, c.604T 5′-GATTCCAGAAGTCAGGA 
CACA-3′, c. 605G 5′-GATTCCAGAAGTCAGGACAC-3′, and 
c.605° 5′-GATTCCAGAAGTCAGGACAT-3′) under stringent 
thermal conditions (94°C/3’, 40 cycles at 94°C/15”, 67°C/15”, and 
72°C/15”, 72°C/3’).
The GNAS locus fragment bearing MAS/FD -associated 
variants was investigated by COLD-MAMA PCR, as previously 
described (de Sanctis et al., 2017).
The dPCR was performed with the QuantStudio™ 3D Digital 
PCR System platform (all products by ThermoFisher Scientific, 
Carlsbad, CA, USA) and predesigned FAM-labelled TaqMan® 
Mutation Detection Assays, GNAS_27895_mu (c.605G > A), 
and GNAS_27887_mu (c.604C > T). Briefly, 1 μl of 5 ng/μl DNA 
(A260/280 ratios between 1.7 and 1.9) diluted in 14 μl of reaction 
mixture (8 μl QuantStudio™ 3D Digital PCR Master Mix, 1.6 
μl TaqMan® Mutation Detection Assay, and 4.4 μl nuclease-free 
water) were loaded into QuantStudio™ 3D Digital PCR 20K 
Chips and amplified (thermal conditions: 1 cycle at 96°C/10’, 
40 cycles at 66°C/1’, and 98°C/45’, 1 cycle at 60°C/1’). Fluorescence 
on chips was revealed by the QuantStudio™ 3D Instrument, 
and collected raw data were analyzed by the QuantStudio™ 3D 
AnalysisSuite™ Software. The software assesses reliable data and 
displays quality indicators, based upon loading, signal, and noise 
characteristics, for each chip. This quality control is based on 
the number of partitions that exceed the total number of wells 
filled correctly, and to get a precise quantification, we settled a 
threshold of 10,000 data points with a manually fixed quality 
threshold over 0.6. Performance experiments conducted for both 
assays determined the appropriate fluorescence thresholds in 
FAM relative fluorescence units (RFU) to discriminate between 
positive calls (blue dots) and no target control calls (yellow dots) 
(Figure 1): GNAS_27,895_mu RFU > 3,000 and GNAS_27,887_
mu RFU > 5,000. The output data are reported as copies/μl 
(cpm) detected on the chip by the instrument that represents 
the number of observed mutant alleles in the reagent mixture 
plus DNA. The absolute quantification of mutated alleles can be 
deduced from the cpm by applying the following formula: cpm X 
0.0033 ng (mass of the human genome) X 3.34 (dilution factor 
for 15 μl of sample plus reaction mixture) = ng/μl.
The specificity and the sensitivity of the dPCR technique were 
assessed testing NTCs, WTCs, and MTCs, previously identified 
by Sanger sequencing, and a calibrator curve, in triplicate, of 
serially diluted mutated samples (representing 100% MTCs), 
ranging from 50% to 3% and from 25% to 1.5% of c.604 or c.605 
heterozygously mutated samples, respectively, representing the 
relative mutation abundance (RMA). Cutoff values, or rather 
copies of mutated DNA per 1 μl of the tested sample, cpm, to 
diagnose the presence of a mutation and the RMA in each 
patient’s sample were then inferred by comparing observed cpm 
values with those detected by the calibrator curve.
RESULTS
The bulk of experiments performed allowed to obtain a molecular 
diagnosis in MAS/FD subjects that were still missing because of 
the low detection rate of the Sanger sequencing, thanks to the 
setup of the dPCR, a highly sensitive and specific technique 
to detect low-abundance somatic single-nucleotide GNAS 
alterations. To validate results produced with the dPCR, we also 
Mosaic GNAS Activating Variants by dPCRElli et al.
4 September 2019 | Volume 10 | Article 862Frontiers in Genetics | www.frontiersin.org
compared this novel approach with additional available methods 
to search for somatic genetic alterations, the AS-PCR and the 
COLD-MAMA PCR.
We started our investigation with a careful analysis of Sanger 
electropherograms obtained by both calibrator curves and MAS/
FD patients, showing that the mutated allele was clearly detectable 
only in case of samples containing elevated amounts of mutated 
DNA (LOD > 0.1 ng/μl) but only conceivable for lower RMAs 
(Figure 2; Table 2). As a matter of fact, the high background 
noise was a side effect that made it impossible to discriminate 
real calls from nonspecific signals, thus leading to the failure to 
establish patients’ genotype conclusively.
FIGURE 1 | Representative 2-D scatterplots obtained from the raw imaging data analysis of rare mutation detection analysis using the QuantStudio™ 3D 
AnalysisSuite™ Software (upper panel: GNAS_27895_mu assay; lower panel: GNAS_27877_mu assay). Blue dots represent the FAM™ reporter dye signal that 
allows to identify and count mutant alleles present in the nanoscale-sized reaction wells of the chip. Yellow dots are the assay control signal and represent the 
absence of FAM™ signal in part of the nanoscale-sized reaction wells of the chip.
Mosaic GNAS Activating Variants by dPCRElli et al.
5 September 2019 | Volume 10 | Article 862Frontiers in Genetics | www.frontiersin.org
In particular, the Sanger sequencing detected somatic 
mutations only in 6 of 79 tested DNA samples (5/15 BO, 33.3%; 
0/16 CB/FB, 0%; 1/11 OC/OCL/OT, 9%; 0/37 BL, 0%) belonging 
to 4 of 54 different patients (7.4% detection rate) (Supplementary 
Table 2; Tables 1 and 2 panel A). No patient affected by the 
c.604C > T variant was found. On the other hand, four patients 
(pt2-BO, pt3-BO, pt37-BO-LJ+M+RJ, and pt46-OC) obtained a 
positive diagnosis for the c.605G > A variant. The pathogenetic 
variant was found by Sanger only in DNA samples extracted from 
affected biopsies. These data further highlighted the technical 
limitations in performing a rare mutation investigation by Sanger 
in DNA samples from whole blood.
The use of allele-specific primers allowed to slightly improve 
the detection threshold of MAS/FD-related variants (LOD  > 
0.03 ng/μl) as it discovered 13 samples/66 with the c.605A 
variant, belonging to 7 of 46 different patients: pt2-BO, pt3-BO, 
pt28-BL, pt37- BO-LJ (left jaw)+RJ (right jaw), pt52-BL+CB, 
pt46-OC, and pt48-BL+OC), but the sensitivity of the AS-PCR 
(19.6% detection rate) was still too low to perform an accurate 
molecular diagnosis of MAS in most patients (Supplementary 
Table 2; Tables 1 and 2 panel A; Figure 3). All Sanger-positive 
samples were confirmed, and three novel positive patients were 
found. It is noteworthy that, contrary to Sanger, this method 
allowed to discover a mutation even in three blood samples (5/10 
BO, 40%; 1/16 CB/FB, 6.25%; 4/10 OC/OCL/OT, 40%; 3/33 BL, 
9.1%) (Table 2 panel A). No false-positive/negative results were 
obtained, and the interindividual and intraindividual, or rather 
different tissues from the same patient, differences in RMAs were 
the same as observed by dPCR, thus excluding an artifact or 
carryover contamination.
Forty samples from 24 patients were prepared for the COLD-
MAMA PCR but, because of the insufficient amount of available 
DNA, only 24 samples from 14 patients for the c.604C > T and 
26 samples from 14 patients for the c.605G > A were successfully 
analyzed, demonstrating the presence of the T-mutated allele in 
2/24 samples (pt41-BL and pt44-OCL) and of the A-mutated allele 
in 12/26 samples (pt6-BO, pt37-BL+BO-LJ+RJ, pt46-OC+OT, 
pt47-OT, pt48BL+OC, pt49-OC, pt50-OC+OCL), showing the 
presence of a MAS/FD causative genetic variant in 9 of 14 patients 
with an overall detection rate of 64.3% (3/3 BO, 100%; 0/2 CB/
FB, 0%; 7/10 OC/OCL/OT, 70%; 2/11 BL, 18.1%) and a LOD > 
0.02 ng/μl (Supplementary Table 2; Tables 1 and 2 panel A).
The first phase of dPCR data analysis, performed using the 
QuantStudio™ 3D AnalysisSuite™ Software, relied on manual 
examination and thresholding 2-D scatterplots from control 
samples (NTCs, WTCs, and MTCs) (Figure 1). Neither false-
positive nor false-negative was observed among tested WTCs 
(c.604T n = 9, c.605A n = 13) and MTCs (c.604T n = 3, c.605A 
n = 6), confirming the good performance of both assays. Thus, 
the dPCR allowed to discriminate all tested MTCs from WTCs.
From calibrator curves of serially diluted MTCs, mimicking 
various RMAs, we determined the LOD of 0.01 ng/μl, reference 
cpm values were used as cutoffs for inferring the presence of a 
GNAS somatic mutation in patients and the RMA in each patient’s 
sample (Figure 4). According to the t test (95% CI), all points 
of the serial curve resulted differently from 0% RMA samples, 
and statistically significant cutoffs to detect the positiveness of a 
sample were 0.391 ± 0.074 (P = 0.0028) for the c.604T and 0.464 ± 
0.012 (P = 0.0004) for the c.605A alleles. Note that TaqMan® 
Mutation Detection Assays showed distinct lower detection 
thresholds, 3% RMA for the GNAS_27887_mu (p.Arg202Cys) 
and 1.5% RMA for the GNAS_27895_mu (p.Arg202His), but the 
best fitting explanation for this slightly contrasting performance 
was the use of DNA serial dilutions prepared from MTCs with 
a different starting concentration and, consequently, a different 
RMA (0.13 ng/μl and RMA 12.11 ± 0.023 and 0.19 ng/μl and 
RMA 17.47 ± 0.177, respectively) rather than a different conduct 
of assays or a setup failure.
During the analysis of patient samples, the short way to call a 
positive sample was by visualizing the 2-D plot and comparing 
cutoff cpm values, considering nonoverlapping error bars, 
between WTCs and unknown samples, whereas a t-test was used 
to determine the correct RMA subcluster attribution of positive 
samples.
The dPCR allowed identification of the mutation in 36/79 
samples (10/15 BO, 66.6%; 3/16 CB/FB, 18.75%; 10/11 OC/OCL/
OT, 90.9%; 14/37 BL, 37.8%) in 23/54 patients (42.6% detection 
rate), of whom 2 patients (pt41-BL and pt44-BL+OCL+OT) 
carried the c.604T variant and 21 patients (pt1-BO, pt2-BO, 
pt3-BO, pt5-BO, pt6-BO, pt12-BO, pt19-BL, pt22-BL, pt25-BL, 
pt28-BL, pt51-BL, pt53-BL, pt37-BL+BO, pt39-BL+CB, 
pt52-BL+CB, pt43-BL+FB, pt46-OC+OT, pt47-OC+OT, pt48-
BL+OC, pt49-BL+OC, and pt50-OC+OCL) the c.605A variant 
(Supplementary Table 2; Tables 1 and 2 panel A). In particular 
FIGURE 2 | Representative electropherograms of the GNAS c.605G > A mutation screening by Sanger sequencing of a mutant control (MTC), a wild-type control 
(WTC), and selected patients (pt37-BO-RJ and pt50-OC). Red arrows highlight the position of the c.605A nucleotide.
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TABLE 1 | Table resuming molecular data of the studied cohort of MAS patients. Cpm, copies/μl. Abs quant, absolute quantification. 
  c.604C>T c.605G>A
PT ID TISSUE SANGER AS-PCR dPCR dPCR 
cpm
dPCR absquant 
(ng/μl)
dPCR 
RMA
COLD-MAMA 
PCR
COLD-MAMA 
RMA
SANGER AS-PCR dPCR dPCR 
cpm
dPCR absquant 
(ng/μl)
dPCR 
RMA
COLD-MAMA 
PCR
COLD-MAMA 
RMA
1 BO WT WT WT 0.181 0.00 WT WT MUT 0.892 0.01 >6
2 BO WT WT WT 0.000 0.00 MUT MUT MUT 8.712 0.10 >50
3 BO WT WT WT 0.095 0.00 MUT MUT MUT 17.626 0.19 100
4 BO WT WT WT 0.000 0.00 WT WT WT 0.169 0.00
5 BO WT nd WT 0.000 0.00 nd WT nd MUT 6.594 0.07 50 nd
6 BO WT WT WT 0.000 0.00 WT WT MUT MUT 3.604 0.04 25 MUT 3
7 BO WT WT WT 0.000 0.00 WT WT WT 0.000 0.00
8 BO WT WT WT 0.086 0.00 WT WT WT 0.353 0.00
12 BO WT nd WT 0.260 0.00 nd WT nd MUT 3.196 0.04 25 nd
9 BO WT nd WT 0.255 0.00 nd WT nd WT 0.084 0.00 nd
37
BL WT WT WT 0.166 0.00 WT WT WT MUT 0.622 0.01 >6 MUT 6
BO-LJ WT WT WT 0.195 0.00 WT MUT MUT MUT 32.654 0.36 100 MUT >40
BO-M WT nd WT 0.000 0.00 nd MUT nd MUT 22.108 0.24 100 nd
BO-RJ WT WT WT 0.169 0.00 WT WT MUT MUT 2.121 0.02 <25 MUT 3
BO-S WT nd WT 0.188 0.00 nd MUT nd MUT 22.904 0.25 100 nd
45
BL WT WT WT 0.087 0.00 WT WT WT 0.312 0.00
BO WT WT WT 0.092 0.00 WT WT WT 0.105 0.00
10 CB WT WT WT 0.152 0.00 WT WT WT 0.343 0.00
11 CB WT WT WT 0.237 0.00 WT WT WT 0.436 0.00
13 CB WT WT WT 0.105 0.00 WT WT WT 0.100 0.00
14 CB WT WT WT 0.000 0.00 WT WT WT 0.185 0.00
38
BL WT WT WT 0.000 0.00 WT WT WT 0.178 0.00
CB-WT WT WT WT 0.183 0.00 WT WT 0.233 0.00
CB-YT WT WT WT 0.105 0.00 WT WT 0.416 0.00
CB-GT WT WT WT 0.173 0.00 WT WT 0.191 0.00
39
BL WT WT WT 0.319 0.00 WT WT MUT 0.509 0.01 6
CB WT WT WT 0.000 0.00 WT WT MUT 1.251 0.01 <12.5
52
BL WT WT WT 0.112 0.00 nd WT MUT MUT 0.598 0.01 6 nd
CB WT WT WT 0.000 0.00 nd WT MUT MUT 6.208 0.07 50 nd
40
BL WT WT WT 0.000 0.00 WT WT WT WT 0.096 0.00 WT
CB WT WT WT 0.320 0.00 nd WT WT WT 0.139 0.00 WT
41
BL WT WT MUT 2.249 0.02 <12.5 MUT <2.5 WT WT WT 0.254 0.00 WT
CB-GT WT WT WT 0.104 0.00 WT WT WT 0.078 0.00
CB-WT WT WT WT 0.000 0.00 nd WT WT WT 0.336 0.00 nd
CB-YT WT WT WT 0.000 0.00 WT WT WT 0.180 0.00
42
BL WT WT WT 0.223 0.00 WT WT WT WT 0.083 0.00 WT
FB WT WT WT 0.265 0.00 WT WT WT WT 0.190 0.00 WT
43
BL WT WT WT 0.188 0.00 WT WT MUT 0.873 0.01 >6
CB WT WT WT 0.000 0.00 WT WT WT 0.089 0.00
FB WT WT WT 0.000 0.00 WT WT MUT 1.633 0.02 >12.5
(Continued)
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TABLE1 | Continued
  c.604C>T c.605G>A
PT ID TISSUE SANGER AS-PCR dPCR dPCR 
cpm
dPCR absquant 
(ng/μl)
dPCR 
RMA
COLD-MAMA 
PCR
COLD-MAMA 
RMA
SANGER AS-PCR dPCR dPCR 
cpm
dPCR absquant 
(ng/μl)
dPCR 
RMA
COLD-MAMA 
PCR
COLD-MAMA 
RMA
35 OT WT nd WT 0.000 0.00 WT nd WT 0.244 0.00
44
BL WT WT MUT 0.777 0.01 <3 WT WT WT WT 0.293 0.00 WT
OCL WT WT MUT 4.995 0.06 <25 MUT <2.5 WT WT WT 0.256 0.00 WT
OT WT WT MUT 1.485 0.02 >6 WT WT WT WT 0.184 0.00 WT
46
OC WT WT WT 0.083 0.00 WT MUT MUT MUT 2.969 0.03 <25 MUT 10
OT WT WT WT 0.182 0.00 WT WT WT MUT 0.520 0.01 6 MUT <0.5
47
BL WT WT WT 0.000 0.00 WT WT WT WT 0.299 0.00 WT
OC WT WT WT 0.102 0.00 WT WT WT MUT 1.135 0.01 <12.5 WT
OT WT WT WT 0.084 0.00 WT WT WT MUT 1.164 0.01 <12.5 MUT 3
48
BL WT WT WT 0.334 0.00 WT WT MUT MUT 5.347 0.06 <50 MUT 16
OC WT WT WT 0.000 0.00 WT WT MUT MUT 10.169 0.11 >50 MUT >40
49
BL WT WT WT 0.101 0.00 WT WT WT MUT 0.465 0.01 3 WT
OC WT WT WT 0.192 0.00 WT WT WT MUT 1.578 0.02 >12.5 MUT 26
50
OC WT WT WT 0.412 0.00 WT WT MUT MUT 3.312 0.04 25 MUT <0.5
OCL WT WT WT 0.205 0.00 WT WT MUT MUT 7.275 0.08 >50 MUT 2.5
15 BL WT WT WT 0.000 0.00 WT WT WT 0.191 0.00
16 BL WT WT WT 0.115 0.00 WT WT WT 0.000 0.00
17 BL WT WT WT 0.154 0.00 WT WT WT 0.264 0.00
18 BL WT WT WT 0.101 0.00 WT WT WT 0.000 0.00
19 BL WT WT WT 0.117 0.00 WT WT WT MUT 0.815 0.01 >6 WT
20 BL WT WT WT 0.097 0.00 WT WT WT 0.119 0.00
21 BL WT WT WT 0.089 0.00 WT WT WT 0.308 0.00
22 BL WT WT WT 0.000 0.00 WT WT MUT 0.644 0.01 6
23 BL WT WT WT 0.000 0.00 WT WT WT 0.219 0.00
24 BL WT WT WT 0.000 0.00 WT WT WT 0.000 0.00
25 BL WT WT WT 0.000 0.00 nd WT WT MUT 2.252 0.02 >12.5 nd
26 BL WT WT WT 0.026 0.00 WT WT WT 0.000 0.00
27 BL WT WT WT 0.000 0.00 WT WT WT 0.000 0.00
28 BL WT WT WT 0.000 0.00 nd WT MUT MUT 2.170 0.02 >12.5 nd
29 BL WT WT WT 0.000 0.00 WT WT WT 0.285 0.00
31 BL WT WT WT 0.095 0.00 WT WT WT WT 0.383 0.00 WT
32 BL WT WT WT 0.277 0.00 nd WT WT WT 0.000 0.00 WT
33 BL WT WT WT 0.000 0.00 WT WT WT 0.190 0.00
34 BL WT WT WT 0.000 0.00 WT WT WT 0.000 0.00
51 BL WT nd WT 0.000 0.00 nd WT nd MUT 1.216 0.01 12.5 nd
53 BL WT nd WT 0.258 0.00 nd WT nd MUT 1.043 0.01 <12.5 nd
54 BL WT nd WT 0.000 0.00 nd WT nd WT 0.246 0.00 nd
30 BL WT nd WT 0.000 0.00 nd WT nd WT 0.171 0.00 nd
36 BL WT WT WT 0.150 0.00 WT WT WT 0.202 0.00
RMA, relative mutation amount; BO, bone; BL, blood; LJ, left jaw; M, maxilla; RJ, right jaw; S, symphysis; CB, cutaneous biopsy; FB, fibroblast; OCL, ovarian cyst liquid; OC, ovarian cyst; OT, ovarian tissue; nd, not determined; WT, wild-type. 
Bold data highlight results obtained in mutated patients.
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and importantly, the technique was able to identify a mutation in 
37.8% of peripheral blood samples.
The comparison of data obtained in seven mutated patients 
from whom we collected both blood and affected tissues (pt37, 
pt39, pt43, pt 44, pt48, pt49, and pt52) ensured the ability of 
dPCR to detect MAS/FD-associated alleles in gDNA extracted 
from blood samples with an RMA sufficient to be ascertained by 
the system.
Curiously, patient 41’s cutaneous biopsy resulted negative for 
alterations, but we found the mutation in two independently 
collected blood samples by both dPCR and COLD-MAMA PCR. 
In patient 43, we found the mutated allele both in the blood and 
in cultured fibroblasts but not in the DNA extracted from the 
cutaneous biopsy (Supplementary Table 2; Table 1).
DISCUSSION
The work presented in this paper aimed at setting up a novel 
technology, the dPCR, to perform the molecular diagnosis of MAS/
FD by the identification of rare somatic activating variants of the 
GNAS gene. The detection of low-level somatic variants in MAS/
FD patients is a challenge for the laboratory because it relies on the 
discrimination between two highly similar sequences, of which 
the wild-type one is significantly more abundant in the sample. 
Molecular procedures currently used in our laboratory, such as 
Sanger sequencing and AS-PCR, do not reach the needed sensibility, 
thus failing to detect rare mutations. For this reason, most MAS/FD 
patients often lack a molecular confirmation of their disease.
Up to now, scientists developed several methods to overcome 
technical limitations associated with performing a successful 
genetic diagnosis of MAS/FD (i.e., enrichment methods with 
subsequent restriction enzyme digestion, RFLP, or with peptide 
nucleic acid probes, PNA, and next-generation sequencing, NGS, 
with or without PNA) (Schwindinger et al., 1992; Liang et al., 
2011; Hannon et al., 2003). Selective enrichment methods reached 
good levels in low-abundance variant identification, but their 
execution is particularly cumbersome and time-consuming, as 
the requirement of a large number of PCR cycles for the selective 
amplification of the mutated allele leads to an elevated risk to 
create PCR artifacts and cross-contamination. An  opportunity 
to overcome these limitations would be an approach such as the 
FIGURE 3 | Representative agarose gels of the AS-PCR for the detection of the c.605G > A variant showing both the aspecific primary PCR on top and the allele-
specific nested PCR below amplicon bands. In the upper gel, as expected, the G-specific amplicon was appreciable for each sample, whereas in the lower gel, 
the A-specific amplicon was detectable only in samples bearing the mutant A allele. Samples 1–9 were MAS patients (1–2 = pt46-OC+OT; 3–5 = pt47-BL+OC+OT; 
6–7 = pt48-BL+OT; 8–9 = pt49-BL+OT), whereas samples 10 and 11 were WTCs.
TABLE 2 | Tables resuming the detection rate of MAS-related c.604T and c.605A GNAS activating variants. 
Sanger AS-PCR COLD-MAMA PCR dPCR
A
BO 5/15; 33.3% 5/10; 50% 3/3; 100% 10/15; 66.6%
CB/FB 0/16; 0% 1/16; 6.25% 0/2; 0% 3/16; 18.75%
OC/OCL/OT 1/11; 9% 4/10; 40% 7/10; 70% 10/11; 90.9%
BL 0/37; 0% 3/33; 9.1% 2/11; 18.1% 14/37; 37.8%
Patients (overall DR) 4/54; 7.4% 9/46; 19.6% 9/14; 64.3% 23/54; 42.6%
B
BO 0/3; 0% 3/3; 100% 3/3; 100% 3/3; 100%
CB/FB 0/2; 0% 0/2; 0% 0/2; 0% 0/2; 0%
OC/OCL/OT 1/10; 10% 4/10; 40% 7/10; 70% 10/10; 100%
BL 0/11; 0% 1/11; 9% 2/11; 18.1% 6/11; 54.5%
Patients (overall DR) 2/14; 14.3% 5/14; 35.7% 9/14; 64.3% 10/14; 71.4%
BO, bone; CB/FB, cutaneous biopsy/fibroblasts; OC/OCL/OT, ovarian cyst/ovarian cyst liquid/ovarian tissue; BL, blood; DR, detection rate.
Panel A reports all patients whereas panel B reports only patients tested by all of the four available techniques. Percentages values are highlighted in bold.
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deep-sequencing NGS (depth of sequence coverage approximately 
800X) with molecular bar code technique, although it is more 
expensive and still far from clinical settings.
During the setup phase, the dPCR allowed to discriminate all 
tested WTCs and MTCs. It showed an extremely high sensitivity, 
being able to detect even few copies of mutated alleles in DNA 
samples extracted from different tissues, including blood samples.
To validate the dPCR approach, we analyzed our samples 
also by Sanger sequencing, AS-PCR, and COLD-MAMA PCR. 
Positive results obtained by Sanger, AS-PCR, and COLD-MAMA 
PCR were in full agreement with those by dPCR.
As expected, the direct sequencing of GNAS exon 8, confirmed 
to be the less sensitive method, was able to reach in our cohort only 
a 7.4% detection rate, which means in only 4 of the 54 analyzed 
patients. Mutated alleles were found exclusively in a small subset of 
biopsies, mainly from bone, whereas no mutation was detected in 
blood samples. The AS-PCR allowed to slightly improve the overall 
detection rate, raising it to 19.6% (7 of 46 analyzed patients) and to 
identify three positive patients directly from the blood-extracted 
DNA, two of them confirmed in the affected tissue as well. The 
COLD-MAMA PCR reached an overall 64.3% detection rate (9 of 
14 analyzed patients) but needed, as the AS-PCR, a large amount 
of starting material with respect to the dPCR that limited the 
opportunity to test all of the patients of our cohort and to compare 
final diagnoses. This method identified almost all mutated tissue 
samples but in only 2 of the 11 blood-extracted samples (18.1% 
detection rate). Finally, the dPCR obtained an overall 42.6% 
detection rate by finding 23 mutated patients of the 54 tested 
ones. In particular, this latter technique discovered low amounts 
of mutated alleles in 14/37 blood samples, with a detection rate 
of 37.8%. (Table 2 panel A). We consider noteworthy to show the 
success rate of the dPCR because of the fact that this technique 
allowed to find false-negative (FN) patients by the other methods 
(19 Sanger FN, 10 AS-PCR FN, and 1 COLD-MAMA PCR FN).
In the present work, we investigated the two most common 
mutations affecting the amino acid residue R202 (previously 
reported as R201), the p.R202H and p.R202C, that account for 
most of diagnosed MAS-associated genetic defects. In ultra-rare 
cases, additional substitutions have been reported at position 202, 
p.R202S/L/G, and at position 228, p.Q228L/R/K/H (Candeliere 
et al., 1997; Riminucci et al., 1999; Lietman et al., 2005; Idowu et al., 
2007). The existance of such exceptional variants and the possibility 
to discover novel activating GNAS defects might explain for the 
portion of MAS patients still missing a confirmative molecular 
diagnosis that includes both true- and false-negative patients.
To compare the efficiency of the different analytical methods 
in detecting mutated MAS/FD patients, we analyzed separately 
the cluster of samples and patients investigated by all four of 
them and determined the detection rate for patients and by 
single sample type. This analysis showed an increase in sensitivity 
leading to the improvement of the detection rate in the considered 
subcohort of 14 cases (14.3% for Sanger, 35.7% AS-PCR, 64.3% 
FIGURE 4 | Graphs of dPCR cpm calibrator curves. On the Y-axis, the copies per μl (cpm) of mutated allele are reported, whereas on the X-axis, the sample 
type (no template ctrls - NTCs. wild-type template ctrls - WTCs and mutated template ctrls - MTCs). Observed reference cpm (mean of triplicates ± SD/% RMAs) 
were 0.102 ± 0.017/0%, 0.391 ± 0.074/3%, 0.563 ± 0.052/6%, 1. 321 ± 0.157/12.5%, 3.035 ± 0.411/25%, 6.855 ± 0.494/50%, and 12.11 ± 0.023/100% for 
the c.604T variant and 0.068 ± 0.06/0%, 0.464 ± 0.012/1.5%, 0.976 ± 0.189/3%, 1.171 ± 0.181/6%, 2.44 ± 0.346/12.5%, 5.17 ± 0.873/25%, and 17.47 ± 
0.177/100% for the c.605A variant. All points of the serial dilution resulted significantly different (CI 95%) from the 0%MTC.
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for COLD-MAMA PCR, and 71.4% for dPCR), indicating dPCR 
as the most performing approach. When we considered the 
testing of specific tissues, we observed that all techniques, but 
Sanger, found the mutated allele in bone samples, whereas in 
ovarian tissues and blood, we noticed a progressive improvement 
in finding rare variants from the lowest by Sanger to the highest by 
dPCR (Table 2 panel B). Moreover, the dPCR approach showed 
to be less susceptible to poor sample quality and to the presence 
of inhibitors because it demonstrated to be able to successfully 
analyze all of the cohort of samples, including very small amounts 
of DNA after long-term storage and FFPE-extracted DNAs. In 
particular, the other methods failed in some cases, which were 
reported as “not determined” in Table 2, because of the reduced 
amount or the poor quality of material available for testing.
Detecting mutated alleles from blood sample was the final 
and more important goal of our study because we wanted to 
obtain an analytical method for the noninvasive testing of MAS/
FD patients, overcoming the need for invasive procedures like 
biopsies. Checking the detection rates in the subcohort of DNAs 
from peripheral blood, dPCR achieved the highest performance 
with respect to the other techniques (54.5% dPCR versus 18.1% 
COLD-MAMA PCR versus 9% AS-PCR versus 0% Sanger) 
(Table 2 panel B). In seven patients, results were cross-confirmed 
by the genotype found in tissue specimens (pt37, pt39, pt43, pt44, 
pt48, pt49, and pt52) (Supplementary Table 2; Table 1). We agree 
with Narumi and colleagues’ (2013) observation that the relative 
mutation abundance in blood is strikingly variable, it does not 
reflect distribution and extension of affected lesions, and it does 
not correlate with disease severity and progression, as already 
observed in other congenital syndromes caused by somatic 
genetic variants (i.e., Proteus and megalencephaly syndromes) 
(Lindhurst et al., 2011; Rivière et al., 2012; Narumi et al., 2013).
Our calibrator curves, being derived from a serial dilution of 
mutated patients and not cloned DNA, allowed a relative rather 
than an absolute quantification of the RMA in samples, and we used 
them to define reference cutoff cpm values to discriminate between 
wild-type and mutated samples. We do not consider this fact as a 
limit of the present study that was aimed at improving the number 
of successful molecular diagnosis of MAS/FD because the absolute 
RMA showed no real utility from a clinical point of view and it 
did not affect the dPCR performance because this method carries 
out an absolute quantitation of nucleic acid samples based on PCR 
amplification and absolute count of single template molecules.
Data from previously published papers showed that the dPCR 
is an extremely competitive method. For example, Lumbroso 
and colleagues (2004) studied a very big series of MAS patients 
and determined the frequency of observed mutated patients in 
several different tissues by RFLP analysis. The dPCR reached 
a better performance in the blood (37.8% dPCR versus 21% 
RFLP) and ovarian tissues (90.9% by dPCR versus 65% by RFLP) 
(Lumbroso et al., 2004).
If we consider ours and Lumbroso’s data on tissue samples, 10 of 
15 (66.6%) and 9 of 11 (82%) bone biopsies, 2 of 14 (14.3%) and 
3 of 11 (27%) cutaneous biopsies, 1 of 2 (50%) and 0 fibroblasts, 
5 of 5 (100%) and 3 of 8 (38%) ovarian cysts, 2 of 2 (100%) and 
13 of 19 (68%) ovarian cyst liquids and 3 of 4 (75%) and 10 of 
13 (77%) ovarian tissues were positive by RFLPs and dPCR, 
respectively (Narumi et al., 2013). Even if ours and Lumbroso’s 
are different techniques, this comparison allowed to appreciate 
the different detection rates of mutated alleles related to the 
specific tested tissue and to confirm, in accordance with Vasilev 
and colleagues (2014), that tissues atypically/rarely involved 
in MAS may have the GNAS mutation in mosaic distribution 
(Narumi et al., 2013; Vasilev et al., 2014).
Bone was the best tissue to identify MAS/FD rare variants, 
which were found both in patients showing isolated FD and the 
classic MAS triad. In both our samples of ovarian cystic fluid, 
we identified the mutated allele, confirming its usefulness also in 
case of isolated precocious puberty. The systematic study of the 
ovarian cystic fluid would be advisable for its major implications 
for both disease progression and treatment.
Our data are also in line with the observation that some 
samples may remain apparently negative because the biopsy 
missed loci where mutated cells are confined, and that 
specimens like skin presented an additional difficulty because 
of the low proportion of melanocytes (Weinstein et al., 1991; 
Schwindinger et al., 1992; Lumbroso et al., 2004; Vasilev 
et al., 2014). In our series, this hypothesis is confirmed by the 
unexpected results obtained in two intriguing cases presenting 
discrepancies between blood and cutaneous biopsies. In 
patient 41, the cutaneous biopsy resulted in negative but 
blood-extracted DNA was positive for a GNAS mutation. An 
artifact was excluded as we confirmed this positive result in two 
independently collected and extracted blood samples by both 
dPCR and COLD-MAMA PCR. The best explanation for this 
finding is the coring of a tissue mainly composed of normal 
cells. This is further supported by our findings in patient 
43 where a mutated allele was detected both in blood and in 
cultured fibroblasts but not in the skin.
This work included a wide and heterogeneous case series, 
reflecting different clinical presentations, as well as various 
sample types. Even if a negative genetic investigation does not 
rule out the clinical diagnosis of MAS/FD, the detection of 
pathogenetic variants associated with MAS/FD is fundamental, 
in particular in partial forms, as it allows early diagnosis.
In conclusion, our data clearly confirm the difficulty 
encountered in performing a successful molecular diagnosis of 
GNAS somatic activating variants, even from tissue specimens. The 
strengths of the dPCR approach were 1) being less susceptible to 
poor quality sample issues (short amplicons), leading to successful 
amplification also of degraded DNA; 2) being less sensitive to the 
presence of inhibitors (sample dilution); 3) very low associated 
risk of cross-contamination (no preamplification cycles required); 
and 4) being cost-effective (1-day processing time and appropriate 
cost of reagent). Overall, the dPCR demonstrated to be a sensitive, 
accurate, and specific analytical tool that we propose should be 
used as the first-line choice for the molecular diagnosis of MAS/FD.
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